公司資料
Gilead Sciences 股價、新聞與催化劑
- 股票代碼:
- GILD
- 交易所:
- NASDAQ
- 產業:
- Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy
- 所在地:
- United States
股票表現
138.92 USD (+0.40%)
收盤價
最後更新: 2026年8月17日
158B USD
市值
股價為何變動
As of Aug 17, 2026, GILD closed up 0.40% at $138.92. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Gilead Sciences is a biopharmaceutical company with deep roots in antiviral therapy and growing exposure to oncology and inflammation. Its story has evolved from a legacy antiviral leader into a broader commercial and pipeline platform.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Gilead has a global commercial footprint with major exposure to the U.S. and Europe. It sits in large-cap biopharma with a strong commercial base.
商業模式特徵
The company generates revenue through branded therapies, lifecycle management, and pipeline reinvestment across multiple therapeutic areas. Investors focus on HIV, hepatitis, oncology, and the ability to keep replacing mature revenue streams with new assets.
生技產業定位
Gilead is a mature large-cap biotech company with enough pipeline depth to retain catalyst sensitivity. It is less binary than development-stage names, but major launch, approval, and partnership updates still matter.
未來催化劑
- Gilead’s biggest near-term catalyst is lenacapavir, especially prevention and filing progress, alongside Trodelvy and the oncology franchise. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。